Corvex Management LP Trimmed Bio Rad Labs (BIO) Position; Fragasso Group Lifted Its Ball (BLL) Holding

December 9, 2017 - By Ellis Scott

Fragasso Group Inc increased Ball Corporation (BLL) stake by 79.89% reported in 2017Q2 SEC filing. Fragasso Group Inc acquired 16,761 shares as Ball Corporation (BLL)’s stock rose 9.29%. The Fragasso Group Inc holds 37,740 shares with $1.59 million value, up from 20,979 last quarter. Ball Corporation now has $13.86 billion valuation. The stock decreased 2.96% or $1.21 during the last trading session, reaching $39.6. About 6.54 million shares traded or 186.68% up from the average. Ball Corporation (NYSE:BLL) has risen 12.13% since December 9, 2016 and is uptrending. It has underperformed by 4.57% the S&P500.

Corvex Management Lp decreased Bio Rad Labs Inc (BIO) stake by 99.88% reported in 2017Q2 SEC filing. Corvex Management Lp sold 846,141 shares as Bio Rad Labs Inc (BIO)’s stock rose 13.43%. The Corvex Management Lp holds 1,000 shares with $226,000 value, down from 847,141 last quarter. Bio Rad Labs Inc now has $7.60B valuation. The stock increased 0.04% or $0.11 during the last trading session, reaching $255.08. About 165,498 shares traded. Bio-Rad Laboratories, Inc. (NYSE:BIO) has risen 53.78% since December 9, 2016 and is uptrending. It has outperformed by 37.08% the S&P500.

Among 4 analysts covering Bio-Rad Laboratories (NYSE:BIO), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Bio-Rad Laboratories had 16 analyst reports since August 7, 2015 according to SRatingsIntel. Deutsche Bank upgraded Bio-Rad Laboratories, Inc. (NYSE:BIO) on Wednesday, June 28 to “Buy” rating. The stock of Bio-Rad Laboratories, Inc. (NYSE:BIO) has “Buy” rating given on Friday, October 20 by Jefferies. Jefferies maintained it with “Buy” rating and $300.0 target in Friday, November 3 report. Wells Fargo maintained it with “Buy” rating and $290.0 target in Wednesday, November 29 report. The rating was maintained by Jefferies on Wednesday, April 12 with “Buy”. The company was maintained on Thursday, July 13 by Jefferies. Jefferies maintained Bio-Rad Laboratories, Inc. (NYSE:BIO) rating on Wednesday, September 7. Jefferies has “Buy” rating and $225 target. The rating was initiated by CL King on Thursday, October 13 with “Buy”. On Thursday, June 8 the stock rating was maintained by Jefferies with “Buy”. The company was maintained on Friday, April 28 by Jefferies.

Investors sentiment decreased to 1.24 in Q2 2017. Its down 0.31, from 1.55 in 2017Q1. It worsened, as 25 investors sold BIO shares while 82 reduced holdings. 41 funds opened positions while 92 raised stakes. 18.06 million shares or 2.63% less from 18.54 million shares in 2017Q1 were reported. Synovus Financial Corp holds 0% or 899 shares. Citigroup holds 0% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 5,326 shares. Bnp Paribas Arbitrage Sa has invested 0.01% in Bio-Rad Laboratories, Inc. (NYSE:BIO). 58,439 were reported by California Employees Retirement. Louisiana State Employees Retirement reported 5,400 shares or 0.06% of all its holdings. The Connecticut-based Verition Fund Mngmt Llc has invested 0.04% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Creative Planning owns 1,381 shares. Portolan Mngmt Ltd Com holds 2.58% or 88,931 shares. Gemmer Asset Mngmt Ltd Limited Liability Company reported 50 shares. Mason Street Lc stated it has 0.06% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Intrepid Capital Management Inc holds 2.24% or 25,304 shares in its portfolio. The Minnesota-based Advantus Capital Mgmt has invested 0.02% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Oregon Employees Retirement Fund reported 7,523 shares. Neuberger Berman Gru Incorporated Ltd Liability Co owns 109,343 shares. Moreover, Royal Bancshares Of Canada has 0% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 3,324 shares.

Analysts await Bio-Rad Laboratories, Inc. (NYSE:BIO) to report earnings on February, 22. They expect $1.27 EPS, up 1.60% or $0.02 from last year’s $1.25 per share. BIO’s profit will be $37.85 million for 50.21 P/E if the $1.27 EPS becomes a reality. After $0.91 actual EPS reported by Bio-Rad Laboratories, Inc. for the previous quarter, Wall Street now forecasts 39.56% EPS growth.

Corvex Management Lp increased Energen Corp (NYSE:EGN) stake by 5.65M shares to 7.00 million valued at $345.50M in 2017Q2. It also upped Bank Amer Corp (Call) (NYSE:BAC) stake by 3.00M shares and now owns 6.00 million shares. Signet Jewelers Limited (NYSE:SIG) was raised too.

Among 14 analysts covering Ball Corporation (NYSE:BLL), 9 have Buy rating, 1 Sell and 4 Hold. Therefore 64% are positive. Ball Corporation had 35 analyst reports since October 15, 2015 according to SRatingsIntel. BMO Capital Markets maintained Ball Corporation (NYSE:BLL) on Wednesday, September 27 with “Hold” rating. UBS initiated the stock with “Buy” rating in Monday, October 23 report. The company was upgraded on Tuesday, November 10 by Macquarie Research. Jefferies maintained it with “Buy” rating and $5000 target in Friday, July 14 report. Deutsche Bank maintained the shares of BLL in report on Tuesday, July 18 with “Buy” rating. The company was maintained on Friday, September 29 by Jefferies. The firm earned “Overweight” rating on Thursday, March 31 by JP Morgan. Robert W. Baird maintained Ball Corporation (NYSE:BLL) rating on Tuesday, October 10. Robert W. Baird has “Buy” rating and $45.0 target. The stock of Ball Corporation (NYSE:BLL) earned “Neutral” rating by Robert W. Baird on Friday, November 3. On Friday, June 23 the stock rating was maintained by Jefferies with “Buy”.